Quick Answer
ZyVersa Therapeutics, Inc. reported R&D Expense of $1.11 million for fiscal year 2025.
ZyVersa Therapeutics, Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $1.11M | -37.4% |
| 2024 | $1.78M | -44.5% |
| 2023 | $3.21M | +702.1% |
| 2022 | $399.9K | -92.6% |
| 2022 | $5.41M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $365.1K | -16.3% | -10.9% |
| June 30, 2025 | $409.9K | -42.2% | +58.4% |
| March 31, 2025 | $258.9K | -49.5% | -40.6% |
| September 30, 2024 | $436.0K | -35.3% | -38.5% |
| June 30, 2024 | $709.0K | -41.9% | +38.2% |
| March 31, 2024 | $512.9K | -51.4% | -23.9% |
| September 30, 2023 | $673.9K | — | -44.8% |
| June 30, 2023 | $1.22M | — | +15.6% |
- ZyVersa Therapeutics, Inc. showed a decrease of -37.4% in R&D Expense compared to the prior fiscal year.
- Over the 2022–2025 period, ZyVersa Therapeutics, Inc.’s r&d expense has declined by 79.4% (from $5.41 million to $1.11 million).
- The most recent figure is from ZyVersa Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 31, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: